TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07815626: A Multicenter, Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic

Sponsor: Zhongshan Sansure Hygene Biomedicine Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 240 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,795,976

Rescue Site Savings

+$7,118,744

Unlock Full NCT07815626 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07815626 Rescue Dossier →